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ABSTRACT
Objective: This study examined the ability of the Func-
tional Mobility Scale (FMS) to detect minimal clinically
important differences in mobility status in children with
cerebral palsy (CP) having interventions.
Materials and methods: This prospective longitudinal
study of instrument validation was conducted in a tertiary
care paediatric hospital. A population-based sample of 84
children with CP aged 2-16 years (mean age 8.8 years),
GMFCS levels I-IV recruited from CP clinics. Children
had orthopaedic surgery for deformity correction and ga-
it deviations, including single event multilevel surgery
(SEMLS) or spasticity management with botulinum ne-
urotoxin A (BoNT-A). Responsiveness of the FMS was
examined using change scores and correlation with an ex-
ternal criterion, the Functional Assessment Questionnaire
(FAQ) at four time points following the interventions.
Comparison of the SEMLS and botulinum groups was
used to examine the ability of the FMS to detect both
change and stability in mobility status.
Results: Correlation of changes score between the FMS
and FAQ showed six significant correlations, however the
correlations were low overall (Spearman rho 0.01-0.36).
More change on the FMS was seen in children who had
SEMLS compared to those who had botulinum toxin in-
jections.
Conclusion: The FMS was able to detect minimal clini-
cally significant change in mobility in children with CP
who had orthopaedic surgery and spasticity management.
Key words: Outcomes assessment, cerebral palsy, res-
ponsiveness, rehabilitation
ÖZET
Amaç: Bu çalýþma tedavi gören serebral palsi (SP) li ço-
cuklarda mobilite durumunda klinik olarak önemli en dü-
þük deðiþimi tespit etmede Fonksiyonel Mobilite Skalasý-
nýn (FMS) becerisini araþtýrdý.
Materyal-metod: Bu çalýþma bir üçüncü basamak pedi-
yatri hastanesinde yapýlan propektif longitudinal validas-
yon çalýþmasýdýr. Çalýþmaya SP kliniklerinden, populasyon
tabanlý, SP tanýsý almýþ yaþ ortalamalarý 2-16 yýl (ortalama
8.8 yýl), GMFCS düzeyi I-IV olan 84 çocuk alýndý. Çocuk-
larýn deformite ve yürüme anomalisi düzeltimi amaçlý tek
aþamalý çok seviyeli cerrahi (SEMLS) veya botulinum ne-
urotoxin A (BoNT-A) ile spastisite tedavisi öyküsü vardý.
FMS nin yanýt baþarýsý deðiþim skorlarý ile ve tedavi son-
rasý dört noktada, dýþ bir kriter olarak seçilen Fonksiyonel
Deðerlendirme Sorgulamasý (FAQ) arasýndaki korelasyo-
nun araþtýrýlmasý ile deðerlendirildi. SEMLS and botuli-
num gruplarýnýn karþýlaþtýrýlmasý ile FMS'nin mobilite du-
rumundaki stabilite ve deðiþimi yakalayabilmesi deðerlen-
dirildi.
Bulgular: FMS ve FAQ deðiþim skorlarý arasýndaki kore-
lasyon altý farklý korealsyon gösterdi ancak korelasyonlar
genel olarak düþüktü (Spearman rho 0.01-0.36). SEMLS
olan çocuklarda botulinum grubuna göre FMS'de daha
fazla deðiþim gözlendi.
Sonuç: FMS ortopedik cerrhai ve spastisite tedavisi gören
çocuklarda mobilitede minimum klinik anlamlý deðiþimi
yakalayabilmektedir.
Anahtar kelimeler: Sonuç deðerlendirimi, serebral palsi,
yanýt baþarýsý, rehabilitasyon.
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INTRODUCTION
This study examined the responsiveness to change of
the Functional Mobility Scale (FMS) in children with
cerebral palsy (CP) following orthopaedic surgery and
botulinum toxin injections. The FMS is a six level cli-
nician administered self-report ordinal scale that rates
mobility within the different environmental settings of
the home, school and community based on the assis-
tance children require (1) (Figure 1). It is an evaluative
measure designed to measure the magnitude of longi-
tudinal change in individuals or groups over time and
to quantify treatment benefits (2). A fundamental
property of evaluative instruments is proven respon-
siveness to change to ensure they can accurately detect
change in function (2-8) 
There is a lack of consensus in the literature
regarding the definition of responsiveness (9, 10). For
the purposes of this article responsiveness is defined
as the ability of a measure to detect minimally clinical
important differences in function when change is
believed to have occurred (4). Internal responsiveness
describes the ability of a measure to assess change over
a pre-specified time frame, and external responsiveness
reflects the extent to which changes in a measure over
52
time relate to corresponding changes in a reference
measure of health status (9). This study focuses on
external responsiveness because it has a broader appli-
cation by concerning the measure itself, rather than the
treatment under investigation (9). An important aspect
of assessing responsiveness is determining what con-
stitutes a minimally clinical important difference
(MCID) (4). The MCID is not a fixed property of the
instrument and depends on each particular question
being investigated. It requires a judgement, which is
often subjective, as to what constitutes clinically
important change (10). The MCID for the FMS has
not previously been investigated.
The aim of this study was to examine the ability of
the FMS to detect minimal clinically important differ-
ences in mobility status, where change occurs, in chil-
dren with CP having interventions. It was hypothe-
sized that the FMS would be able to detect change and
that it would show initial deterioration in mobility and
subsequent improvement for children having major
multilevel surgery and relative stability in mobility for
children having injections of botulinum neurotoxin A
(BoNT-A).
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Figure 1.  The Functional Mobility Scale 
METHOD
This prospective longitudinal study used a consecutive
sample of children. The study was approved by the
institutional ethics committee of the centre where the
study was performed as well as the associated universi-
ty ethics research committee. Children were recruited
consecutively from the orthopaedic CP clinics and gait
laboratory of a tertiary care institution. All eligible chil-
dren were invited to participate by the first author prior
to their interventions. Written consent was obtained
from each participating child's parent or legal guardian.
Included were children with CP aged 2-18 years,
classified as Gross Motor Function Classification
System (11) levels I-IV, who were scheduled to have
orthopaedic surgery or spasticity management between
January 2006 and May 2007. Excluded were children
whose parents were not able to understand what was
required of them due to cognitive or language prob-
lems.
The interventions included in the study were; 1)
bilateral single event multilevel surgery (SEMLS) for
gait correction, 2) botulinum toxin injections into spe-
cific muscles for lower limb spasticity management and
3) other types of surgery including single level
orthopaedic surgery for deformity correction (for
example bony foot surgery or hamstrings surgery in
isolation) and surgery for hip displacement (including
varus derotation osteotomies and adductor longus
lengthening with Phenol to the obturator nerve).
These categories were chosen because they reflected
the range of interventions routinely embarked on at
the centre where the study took place.
SEMLS refers to the correction of all orthopaedic
deformities in one session (12). It can be defined as at
least two orthopaedic procedures at different anatomi-
cal sites in each limb i.e. a minimum of four proce-
dures (13). The frequently used procedures are muscle-
tendon lengthenings, tendon transfers, rotational
osteotomies and bony stabilisation procedures (14).
Injections of Botulinum toxin A are used to treat spas-
ticity in selected muscle groups resulting in temporary
chemodenervation of muscle (15). Injections are indi-
cated primarily in younger children aged between 2 and
6 years (15, 16) to prevent the development of fixed
contractures (12).
All categories of interventions were used in the
correlations of overall change with an external criteri-
on. In addition, the SEMLS and botulinum toxin
group were isolated and analysed separately to examine
change versus relative stability in mobility status. It was
expected that there would be deterioration in mobility
and subsequent improvement in the children having
SEMLS based on a previous study that examined
change over a 2 year period following SEMLS (17).
Clinical experience suggests that the mobility status of
children who have botulinum toxin does not change
significantly and these children were expected to have
stable mobility following the injections. The
orthopaedic surgeon responsible for each child's man-
agement prescribed the surgery and performed the
surgical operations or injected the botulinum toxin.
A sample size of 80 was aimed for based on a pre-
vious study of the FMS which found it was able to
show change in 66 children with CP following SEMLS
(17). This number would also allow for comparison
between the group of children having SEMLS and
those having botulinum toxin injections.
Pre-operatively and at each post-operative time
point each child's GMFCS level was determined by the
first author, an experienced physiotherapist. Other
data collected for each child were; 1) an FMS rating
administered by one of three experienced physiothera-
pists who were blind to the hypotheses of the study,
and 2) the walking scale of the Gillette Functional
Assessment Questionnaire (FAQ) (18) completed by
the parents. The FAQ is a 10 level parent report ordi-
nal scale that also assesses mobility and has been
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Table-I 
Participant characteristics.  
Characteristic  Total group SEMLS group Botulinum toxin group 
n          84 24 25 
Age (y,m), mean (SD), range                        8.8 (3.3), 2-16 10.3 (1.8), 7-14 6.6 (2.6), 2-12 
Sex, n (%)                     Male          59 (70%) 16 (67%) 15 (60%) 
                                    Female          25 (30%) 8 (33%) 10 (40%) 
GMFCS, n (%)                  I          10 (12%) 1 (4%) 4 (16%) 
                                          II          31 (37%) 11 (46%) 9 (36%) 
                                          III           35 (42%) 11 (46%) 10 (40%) 
                                          IV          8 (9%) 1 (4%) 2 (8%) 
y.m: years:months,  SD: standard deviation,  SEMLS: single event multilevel surgery 
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shown to be reliable and valid (18). It differs from the
FMS in that it has only one item and does not take into
account the assistive devices the children require for
mobility. The children were assessed at regular post-
intervention time points; 3, 6, 9 and 12 months post
SEMLS and 3, 6, 12 and 24 weeks post injections. At
each post-intervention time point the child's GMFCS
level, FMS rating and FAQ score were collected. The
children did not have any additional surgery or injec-
tions before the last-follow-up.
Descriptive statistics for participant characteristics
were calculated. The MCID was considered to be a
change of one category up or down on the FMS based
on consensus by four experienced clinicians. This deci-
sion was based on the literature that clinical experience
with a measure is a valid method of determining the
MCID where there is no "gold standard" for what rep-
resents a real change in clinical status (19). Each cate-
gory within the FMS represents a different level of
assistance required for mobility. A change of one level
up or down therefore is a clinically meaningful level of
improvement or deterioration. Measures of external
responsiveness appropriate for categorical data were
chosen to examine the responsiveness and the FAQ
was used as an external criterion to assess change fol-
lowing the interventions.
Change scores (follow-up score minus initial score)
for each post-intervention stage were used as a meas-
ure of responsiveness because FMS and FAQ data are
ordinal (3). The percentage of children who either did
not change or changed for the better (up) or worse
(down) was calculated at each time point. This was
done for the group as a whole as well as for the group
who had SEMLS compared to the group who had bot-
ulinum toxin injections. This was to determine whether
the FMS could show change as well as stability because
a useful measure must reflect "no change" as well as it
does "change" (9). Spearman rank correlation coeffi-
cients (20) were calculated for the correlation of
change scores for each distance of the FMS with the
FAQ over each time period based on groups of no
change, improved or deteriorated.
The data were stored and organised using the
EpiData for Windows program
(http://www.epidata.dk/.). All analyses were per-
formed using Stata [StatCorp 2005 Stata statistical soft-
ware Release 9.0. College Station; TX. Stata Press].
RESULTS
Ninety six children were recruited for the study. Nine
children dropped out of the study in the initial period
due to parents not returning the FAQ in the mail.
Another three children recruited did not have their sur-
gery on the expected date within the recruitment peri-
od. This left a total sample of 84 children. The chil-
dren had a mean age of 8.8 years (range 2-16 years).
There were 59 males and 25 females. Table 1 sum-
marises the participant characteristics.
Twenty four children (29%) had bilateral SEMLS,
25 (30%) had botulinum toxin injections and 35 (41%)
had other types of surgery. The mean age of the chil-
dren who had SEMLS was higher than that for those
who had botulinum toxin injections.
The correlations between change scores on the
FMS and FAQ using Spearman rank correlation coef-
ficients are presented in Table 2. The correlations were
generally low with only six comparisons statistically
significant.
The change scores are shown in Table 3. The per-
centages of children who showed no change, changed
up one or more level (change for the better) and
changed down one or more level (changed for the
worse) based on the MCID of one category at each
post-intervention time point compared to baseline are
presented. This is for the group as a whole and for the
SEMLS and botulinum toxin groups.
For the group as a whole there were more than
50% of children who did not change at each time point
on the FMS compared to baseline. There was more
change for the FAQ. At the first post-intervention time
point more children showed deterioration than
improvement but the levels were relatively even at the
second time point. At the third and fourth time points
more children improved than deteriorated compared
to baseline.
A pattern emerged when comparing children who
had SEMLS with those who had botulinum toxin
injections. A greater number of children showed no
change on the FMS and FAQ in the toxin group at
each time point. Children who had SEMLS showed
change, particularly at the first time point with more
than 50% deteriorated on all three FMS distances. The
differences in change in these two groups can be clear-
ly seen in the bar graphs in Figures 2-4. The graphs
illustrate greater change in the SEMLS group com-
pared to the relative stability of FMS in the botulinum
toxin group for each FMS distance.
DISCUSSION
The results of this study provide some evidence of the
responsiveness to change of the FMS. A higher per-
centage of children who had SEMLS changed com-
pared to those who had botulinum toxin injections,
thus suggesting the FMS is able to detect both change
and relative stability in the mobility status of children
with CP.
RESPONSIVENESS OF THE FUNCTIONAL MOBILITY SCALE..., Harvey54
FTR Bil Der - J PMR Sci  2009;12:51-58
The differences in change observed were expected
based on previous research examining changes in
mobility following  SEMLS (17) and indications for
botulinum toxin. One of the aims of the botulinum
toxin injections is to prevent the development of fixed
contractures (12) and defer the need for more exten-
sive deformity correction until the child is at an opti-
mal age where the most benefits are obtained from
surgical interventions (14). Thus, children who have
botulinum toxin injections tend to be younger than
those having SEMLS as seen in the differences in the
participant characteristics of each group in this study.
Because botulinum toxin injections result in temporary
chemodenervation of targeted muscles to improve
muscle length (15), it is not expected that mobility sta-
tus will change significantly. SEMLS on the other hand
is more invasive and aims to correct musculoskeletal
deformities contributing to gait deviations (21). It is
expected that following SEMLS mobility will deterio-
rate in the initial post-operative phase and then
improve as the children become stronger and the gait
pattern improves throughout the rehabilitation period.
Responsiveness in this study was examined using
the FAQ as an external criterion. The correlations of
change scores on the FMS with change scores on the
FAQ were lower than expected. This possibly reflects
the differences between the two measures. The walking
scale of the FAQ is a one item 10 level categorical scale
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Table-II 
Correlation of change scores between the FMS and FAQ.  
Change period  FMS distance Rho p value 
Change from baseline to first post intervention 
point  
5 0.28 0.0088* 
50 0.36 0.0007* 
500 0.23 0.04* 
Change from baseline to second post 
intervention point  
5 0.17 0.1282 
50 0.18 0.1075 
500 0.06 0.6016 
Change from baseline to third post intervention 
point  
5 0.01 0.5815 
50 0.26 0.03* 
500 0.04 0.7391 
Change from baseline to fourth post 
intervention point  
5 0.05 0.7279 
50 0.29 0.05* 
500 0.22 0.14 
* denotes statistically significant result 
Table-III 
Percentage of children (%) changed from baseline categories for the FMS and FAQ at post-intervention time points.  
Time 1st time point  2nd time point 3rd time point 4th time point 
Change 0 v  ^ 0 v  ^ 0 v  ^ 0 v  ^
Total (n=84)             
FMS 5 60 33 7 74 14 12 73 8 19 65 15 20 
FMS 50 57 38 5 67 17 16 60 13 27 63 13 24 
FMS 500 67 27 6 70 12 18 71 9 20 85 6 9 
FAQ 40 47 13 49 24 27 45 19 36 30 22 48 
SEMLS (n=24)             
FMS 5 29 62 9 54 34 12 50 21 29 52 24 24 
FMS 50 37 59 4 58 25 17 59 12 29 52 10 38 
FMS 500 42 50 8 54 26 20 59 16 25 81 14 5 
FAQ 25 67 8 52 26 22 44 26 30 24 23 53 
BOTOX (n=25)             
FMS 5 88 4 8 92 4 4 88 0 12 74 9 17 
FMS 50 84 12 4 80 4 16 71 8 21 74 13 13 
FMS 500 96 4 0 100 0 0 96 0 4 92 0 8 
FAQ 64 20 16 64 12 24 50 13 37 39 17 44 
 0; no change, ↓; changed down by at least 1 category (worse), ↑; changed up by at least one category (better) 
SEMLS: single event multilevel surgery group,  BOTOX; Botulinum toxin group 
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where one category is chosen by the parent to reflect
the child's usual walking ability. The FMS is a six level
categorical scale using clinician interpretation of self
or parent report and has three different items report-
ing three different levels of mobility according to envi-
ronmental setting. Although they are both measuring
mobility, the methods of reporting differ. Correlations
of change scores were calculated for all three FMS
items with the FAQ. It is interesting to note that there
were higher correlations of the FAQ with the FMS 50
meter distance, suggesting that of the three FMS dis-
tances the 50 meter distance is most closely related to
the FAQ. The higher number of levels to select from
on the FAQ may have resulted in a higher variability of
categories chosen, with a smaller chance of selecting
the same category each time.
Considering the differences between the scales a
different external criterion might have produced high-
er correlations. A major difference between the scales
is that children can improve or deteriorate in mobility
as measured by the FMS and remain in the same 
category on the FAQ. This is because the FAQ does
not consider the assistive devices children use. This
implies that although both scales measure mobility,
their underlying constructs are different. There is,
however, no other scale or measure that can be consid-
ered a "gold standard" for mobility to use as an alter-
native external criterion. A weakness of relying on an
external standard to assess responsiveness is that a new
outcome measure may be designed specifically because
it reflects a different aspect than currently available
measures (9). The FMS was developed because no
other measures available considered the assistive
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Figure 2.  Change in FMS 5m score of botulinum group 
compared to SEMLS group 
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Figure 3.  Change in FMS 50m for botulinum group 
compared to SEMLS group 
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Figure 4.  Change in FMS 500m in botulinum toxin 
group compared to SEMLS group 
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devices children use in different environmental set-
tings. It therefore measures different aspects of mobil-
ity than the FAQ. Other methods of assessing respon-
siveness that do not require the use of an external cri-
terion, such as effect size and standardized response
means, are not appropriate for categorical data. These
methods tend to assess the magnitude of treatment
effect rather than the ability of the tool to detect clin-
ically important differences and do not provide infor-
mation about the quality of the instrument to serve its
purpose (10).
Another option for a criterion measure in the
absence of a gold standard that has been suggested is
using parent or clinician judgment (3). Parental opin-
ions can be subjective and potentially introduce a bias
in reporting. It is possible for an instrument which
includes some subjective components to detect differ-
ences between interventions and thus suggest respon-
siveness without being a valid measure (5). These sub-
jective methods of change were not chosen for this
study because of the lack of evidence for reliability
and validity of such methods. Determining the best
methods for assessing responsiveness of evaluative
tools remains an ongoing process.
There are some limitations of this study. The sam-
ple included more children classified as GMFCS levels
II and III as this reflects the demographic of children
who are appropriate for spasticity management and
orthopaedic surgery for gait correction. The children
were recruited from one centre only. Further investiga-
tions of the responsiveness of the FMS with children
from a range of centers with a more even spread of
GMFCS levels is appropriate. It is also important to
demonstrate the FMS is able to detect changes in
mobility following other interventions such as physio-
therapy programs and other forms of spasticity man-
agement as well as changes that occur that are not
related to interventions as children grow and develop
over time.
The FMS is measured on a categorical scale and
this limits the range of statistical methods that can be
used to analyze the data. A different criterion measure
such as the mobility domain of the Pediatric
Evaluation of Disability Inventory (PEDI) (22) or the
Activities Scale for Kids (ASK) (23) may have been
more suitable. Receiver operating characteristic (ROC)
curves could have been used for data analysis (9). They
were not used due to the lack of a completely stable
group to compare change against. Clinical experience
suggests that children having botulinum toxin injec-
tions show less change,, however there is no expecta-
tion that this group would be completely stable.
In conclusion, the FMS was able to detect changes
in mobility in children with CP. The FMS was able to
detect more change in children who had SEMLS com-
pared to those who had botulinum toxin injections.
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